ABSTRACT At the present time, only large multinational pharmaceutical companies have the financial ability to research new drugs. Thus, reducing the research and development costs of new drugs is an important subject. Through the in-depth mining of existing drug data, this paper aims to classify unknown drugs and provide assistance for drug screening during the development process. This will reduce the costs of original drug research and promote the transformation of China's pharmaceutical industry. In this paper, we first collected a drug data set using a Web crawler. Based on this data set, we derived a formula for calculating the similarity between drugs and identified the parameters of the similarity calculation formula from a subset of the data. We used the k-nearest neighbor classifier to categorize the drug data based on the similarity of medicines. The results show that the proposed drug classification model can achieve 77.7% accuracy, which is far better than the classification performance of a decision tree and a random forest with only one decision tree, similar to that of a random forest with 10 decision trees, and worse than that of a random forest with 500 decision trees. Although the classification method proposed in this paper is reasonable and the experimental results are in line with expectations, the proposed technique could be improved to manage problems, such as overfitting. Because this classification method is based on chemical similarity and depends entirely on the available training data (which are limited), such fitting problems are inevitable. To solve this problem, more data are needed and the existing sampling method should be improved. One possible approach is to combine this algorithm with ensemble learning techniques to avoid the phenomenon of overfitting.
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I. INTRODUCTION

I
N THE pharmaceutical industry, drugs can be divided into two categories according to their level of innovation: those produced from original research and generic drugs. The development of new drugs typically takes approximately 15 years and billions of dollars of funding, in addition to rigorous clinical trials. Because of the enormous research and development costs, only large multinational pharmaceutical companies have the ability to develop new drugs. Generic drugs are often developed by small pharmaceutical companies during the period of patent protection of the original drug. Generic drugs do not require rigorous clinical trials [1] , but the research and development of these drugs during the period of protection does run the risk of patent infringement. Although the research and development costs of new drugs are high, the process is very profitable because pharmaceutical companies control drug pricing during the patent protection period.
Before new drugs can enter the market [2] , they must be approved. The approval time is approximately 25 months, although it can extend to 40 months.
The length of time required to gain approval from the State Food and Drug Administration is closely related to the fact that the administration is completely dependent on manual operations. If there are a large number of new drugs to be approved, a backlog in the approval procedures delays their entry into the market, which can affect the economic benefits gained by pharmaceutical companies. If we could automate the classification of drugs, it would greatly reduce the labor costs of drug classification and accelerate the drug approval rate.
To overcome the limitations of existing methods of calculating the similarity between medicines, this paper proposes a new calculation method that uses the values of the physical and chemical properties of drugs as features. We use the traditional k-nearest neighbor (k-NN) classification algorithm on MapReduce architecture and develop an effective mapping function for the classification of unknown drugs. Our method can play a supporting role in drug screening during the development process, thus reducing the development costs of the original drug. The accurate prediction of drug classification will not only play a significant role in China's pharmaceutical industry, but also accelerate the drug approval process and ease pressure on the State Food and Drug Administration for the approval of new drugs.
II. RELATED WORK
Our work mainly involves two aspects. First, we select a calculation standard, the characteristic value, to calculate the similarity between existing drugs and build relationships among the pharmaceutical network. Second, we use existing data to predict the category of new drugs.
A. CALCULATING THE SIMILARITY BETWEEN MEDICINES
The vector space model (VSM) [3] calculates the similarity between medicines by implementing a cosine formula based on an input vector consisting of various features of a drug. Unlike a text similarity calculation, drugs have many features, such as color, structure, function, and physical and chemical properties. Choosing different features as the basis results in a different degree of similarity. Therefore, the key to drug classification is feature selection.
Regarding feature selection, there are two approaches for calculating the similarity between medicines. The first is the ''target method'' [4] , whereby drug targets are used as classification features to calculate the similarity between medicines. Drug targets are biological macromolecules in the human body that bind the drug, such as nucleic acids and proteins. Those that express the target protein gene are called target genes. According to this idea, Kleinberg proposed the HITS algorithm as part of IBM's ''CLEVER'' project. The target method is highly accurate and provides a credible theoretical basis for drug development. However, it has certain limitations; in particular, the pharmacology network is only suitable for a particular disease, which implies a lack of versatility. Building a pharmacology network for each disease would be very costly.
The second approach is the ''structural method,'' [5] which calculates the similarity between medicines using the drug structure as a feature. For example, Vos et al. used the similarity between the molecular fingerprints of drugs as features to calculate the overall similarity [6] . DNA fingerprinting considers a number of specific substructures present in a molecule. Willett et al. used the Tanimoto coefficient to calculate the similarity between drug molecules as a function of quantization [7] . However, the structural method provides poor resolution with respect to chiral molecules. [8] B. DRUG CLASSIFICATION PREDICTION ALGORITHM There are many classification algorithms in the field of data mining, which can be divided into supervised, semisupervised, or unsupervised learning algorithms according to whether the category of a sample is known.
Data mining algorithms are frequently used to classify chemicals, with research focused on the prediction of new drug targets. For example, Yu et al. [9] used random forests in a support vector machine algorithm to predict drug targets. Yamanishi et al. [10] used a kernel regression method to characterize the chemical structure of medicines by calculating the similarity between them, and also constructed a multilayer protein network that defines the relationship between proteins. Rhodes et al. [11] proposed another new idea for a predictive model of the interaction between novel proteins by selecting certain protein physicochemical parameters, structural features, and other characteristics as attributes.
III. METHODS
In this section, we will present the technology details of our proposed methods. Basing on k-NN classification algorithm, we proposed a novel drug classification algorithm. The innovation of this algorithm is introducing the weighting parameter , we can get the distance between drugs through optimizing the parameter of . Then we classify the drug with the distance using k-NN algorithm.
A. DATA DESCRIPTION
The drug data used in this article were obtained from publicly available data on the Internet. Detailed information about all the medicines can be obtained from Pharmacodia, a big data platform that focuses on pharmaceutical research and development. The drugs can be classified as chemical medicine and biological medicine according to their characteristics.
Drug information includes the drug name, indication, molecular structure, physical and chemical properties, chemical synthesis route, and drug-related patent information. We obtained a total of 3,857 records covering a total of 544 categories.
Pharmaceutical data includes up to 14 categories. However, we encounter problems if we use a multiclassification method. First, the 14 categories greatly increase the complexity of the algorithm because 14 possible outcomes must be generated based on the input data. Second, as the overall dataset is imbalanced, if the data are divided into 14 categories, some categories may contain very few records. In fact, ear, nose, and throat medicine, immune system drugs, and other drugs account for only a small fraction of the overall amount of data. Multi-classification leads to sparse training data, a poor algorithm, and poor classification results. Considering the above factors, we use a binary classification method with anti-tumor drugs, antiinfective drugs, nervous system drugs, cardiovascular system drugs, and blood/endocrine/metabolic system drugs as one class, and all remaining drugs in another class; that is, this study mainly determines whether a drug belongs to the five types in the former class.
The data used in the experiments include drug category information, and physical and chemical properties of drugs, including relative molecular mass, number of hydrogen bond donors, number of hydrogen bond acceptors, flexible rotation key, polar surface area, and hydrophobic constant. An example of the data is presented in Table 1 .
When solving the classification problem, we use existing data to facilitate the description of the model. The following provides a mathematical description of the data obtained: Let X denote a vector of the physicochemical properties of the drug, where each drug represents a sample. Thus, X = {x 1 , x 2 , x 3 , x 4 , x 5 , x 6 }, where x 1 denotes the molecular mass, x 2 denotes the number of hydrogen bond donors, x 3 denotes the number of hydrogen bond acceptors, x 4 denotes the flexible rotation key, x 5 denotes the polar surface area, and x 6 denotes the hydrophobic constant. For example, the drug in the first sample in Table 1 can be expressed as X 1 = {461.46, 1, 9, 4, 125, 2.565}.
B. CHEMICAL CLASSIFICATION MODEL
Suppose there are n samples in the drug dataset χ = {(X 1 , Y 1 ), (X 2 , Y 2 ), . . . , (X n , Y n )}, where each sample is a vector (X n , Y n ). X n denotes the physicochemical properties of a drug and Y n denotes category of a drug. Suppose Y t n is the category in Y n which has a value of drug category, and Y p n is the category in Y n which has no value of drug category. Then, the drug datasets can be divided into two independent subsets χ t and χ p , where
The main task of this paper is to train the classification model from data subset χ t to predict the category of data in χ p , and then provide a predictive value for the null values in Y p n .
1) SIMILARITY CALCULATION BETWEEN DRUGS
The more similar the physical and chemical properties of two drugs, the more similar the drugs are considered to be. Therefore, in the proposed method, the physical and chemical properties of drugs are used as the basis for calculating the distance between drugs; the smaller the distance, the greater the degree of similarity between the drugs. For two drugs classified as X 1 and X 2 , the distance can be intuitively defined as
The six features used to determine drug similarity have different degrees of influence. For instance, the relative molecular mass has a relatively minor influence on drug similarity, whereas chemical reaction characteristics, such as the polar surface area, may strongly affect drug similarity. If we simply use (1) to calculate the similarity between drugs, the importance of the different features will not be reflected.
Hence, we use a weighting parameter = {ω 1 , ω 2 , ω 3 , ω 4 , ω 5 , ω 6 }, where 6 i ω i = 1. Each element corresponds to the weight of a feature value [12] , that is, the weight of feature x 6 is ω 6 . Incorporating these weights, the new distance formula can be expressed as
Calculating the similarity between drugs can then be translated into the problem of determining the distance d between the drugs. For (2), both X 1 and X 2 are known, so the problem involves determining . In the process of determining , d is a non-differentiable function. Thus, we convert (2) to
Different values of provide different distances between drugs, thus it is necessary to determine such that the distance between drugs in the same class is small and the distance between drugs in different classes is large, which is expressed as
where X 0 is an optional sample of class y j , i ( ·X i − ·X 0 ) 2 represents the sum of the distances from the other samples in the same class to selected sample X 0 ,
2 represents the sum of the distances between all types of drugs of the same class, and argmin ω represents the value of obtained when the function attains its minimum value.
To solve (4), we use the gradient descent method and write
Equation (4) can then be expressed as argmin f ( ) .
To determine , we require 6 i ω i = 1. Thus, we add a constraint term λ( ) to (6) . The complete mathematical expression of the problem is then
This standard optimization problem can be solved using the gradient descent method. Once has been determined, we can calculate the distance between any two drugs according to (3).
2) OPTIMIZATION OF THE WEIGHT COEFFICIENT
When the gradient descent algorithm [13] is employed to solve (7), the algorithm converges slowly, especially for large amounts of input data. Therefore, we propose an acceleration algorithm by introducing the following inference step:
where θ k [0, 1) is an inferred parameter that changes on each iteration. To achieve accelerated convergence, these parameters must be selected in a special way. We adopted the same approach as O'Donoghue by using the following formula to select θ [14] :
The process of the algorithm is as follows: 
Using the resulting , the k-NN algorithm is used to classify the samples.
3) CLASSIFICATION BASELINE
Based on the distance between the drugs, the k-NN algorithm is then used to classify them. Specifically, for a drug to be classified as X i according to (3), we calculate the distance between all existing classified drugs from the training set χ and X i . Based on the principle of the k-NN algorithm, we select the k samples with the smallest distance from the given sample and assign the category that appears most frequently for those k samples as the class.
IV. EXPERIMENTAL RESULTS
Because the data to be classified are not labeled, we lack a real indicator to verify the correctness of the labels assigned by the classification algorithm. To solve this problem, we adopted a method of artificial marking, whereby the labels of the drugs to be classified were assigned according to their indications. Although this method is somewhat complex, it is feasible in the case of missing data.
A. RESULTS BASED ON THE K-NN ALGORITHM
After applying the classification model to the test data based on the k-NN algorithm, we obtained the final algorithm for the classification of drugs. To evaluate the accuracy of the classification algorithm, we first conducted a case analysis. From the data, we identified drugs with indications that relate to tumors, cancer, and hepatitis, for which the classification accuracy using the proposed algorithm was 78%, 77%, and 84%, respectively, as shown in Fig. 1 .
Significantly, from the point of view of the aforementioned three diseases, drugs were classified correctly with a probability close to 80%, far better than random chance. This indicates that our proposed algorithm can indeed perform drug classification to achieve the desired objectives.
To further investigate the effect of the overall classification algorithm, we examined all the results. Because of the previously mentioned issue regarding the number of features, we conducted two experiments with different numbers of features for various values of k. By conducting multiclassification within the same experiment, we were able to study the impact of each parameter on the effect of classification. The results are shown in Fig. 2 .
The dashed line in Fig. 2 indicates the established model based on all six features of the original data. The solid line shows the results provided by the model when the relative molecular mass was neglected. As shown in Fig. 2 , the latter produced a better overall classification result. Note that even values of k provide lower classification accuracy than either previous or subsequent odd numbers. This may be because for even values of k, data within the required distance of the sample have a greater probability of being in more than one category. For this case, the algorithm randomly selects a category for the sample.
By observing the accuracy with respect to k, it is clear that k = 3 provides the best results. The overall trend is downward, although some higher values of k may produce better classification results. VOLUME 5, 2017 FIGURE 2. Classification accuracy of different features: solid line produced using five features; dashed line produced using six features.
B. COMPARATIVE EXPERIMENT
To verify the classification performance of the proposed model, we conducted a comparative experiment. The classification method was evaluated in terms of accuracy, recall, and precision [15] . For the binary classification problem, we divided the samples according to their real and predicted categories into true positives, false positives, true negatives, and false negatives. The results using the proposed method were compared with those provided by a decision tree and random forest. The comparison is shown in Fig. 3 .
In Fig. 3 , the accuracy reflects the probability that all drugs are correctly classified; recall rate reflects the probability that drugs classified as anti-tumor drugs, anti-infective drugs, nervous system drugs, and cardiovascular and blood system drugs are indeed in this category; and precision rate reflects the probability that the aforementioned drugs are correctly predicted as such.
It can be observed from Fig. 3 that the classification performance of our proposed method is much better than that of the decision tree algorithm and the random forest algorithm with only one tree. Compared with the random forest with 10 decision trees, our algorithm produces better accuracy but lower recall. The random forest with 500 decision trees outperforms the proposed model in terms of both accuracy and recall. The performance of these five classification algorithms is broadly the same, particularly in terms of the precision metric. The classification performance of the proposed algorithm is similar to that of the random forest with 10 decision trees, and worse than that of the random forest with 500 decision trees. Of course, the complexity of the random forest algorithm increases with the number of decision trees; hence, the execution time of the random forest with 500 trees is longer than that of the proposed method. The time complexity of each algorithm is shown in Fig. 4 , where the vertical axis represents the time complexity on a logarithmic scale. Figs. 3 and 4 indicate that the proposed algorithm has the best classification rate of all methods with a comparable order of time complexity. Compared with the proposed algorithm, the accuracy of the random forest with 10 decision trees is similar, but the time complexity is one order of magnitude greater. The time complexity of the random forest algorithm with 500 decision trees, which achieved the highest accuracy, is three orders of magnitude greater than that of the proposed algorithm. Thus, the method described in this paper achieves a good balance between accuracy and algorithmic complexity.
V. DISCUSSION
In the process of identifying the model parameters, we found that the relative molecular mass does not significantly impact the classification of drugs, as predicted. To evaluate the classification performance of the proposed algorithm, we used a decision tree model and the random forest model to classify the same dataset. A comparison of the results shows that the proposed drug classification model can achieve 77.7% accuracy, far better than the decision tree model and the random forest with only one decision tree. Furthermore, our model achieved similar accuracy to the random forest with 10 decision trees, although it could not match the performance of the random forest with 500 decision trees.
By comparing the proposed algorithm with the random forest algorithm, it can be inferred that the proposed algorithm may suffer from overfitting and have poor generalization ability. These problems will be addressed in future studies.
VI. CONCLUSIONS
In this paper, the category prediction of new drugs was abstracted into a drug classification problem. By studying the intrinsic relationship between the existing large number of drug categories and their physical and chemical properties, a new classification algorithm based on the k-NN chemicals was proposed. We classified various drugs with known physical and chemical properties according to this classification model. The proposed model achieved a classification accuracy of 77.7%, which is better than that of the decision tree model and comparable to the random forest model. The method described in this paper achieves a good balance between accuracy and time complexity. The proposed method can also be applied on other related data sets.
Although the classification method proposed in this paper is reasonable and the experimental results are in line with expectations, the classification method displays some hallmarks of overfitting. Because this classification method based on chemical similarity depends entirely on the available training data, which are very limited, such fitting problems are inevitable. To solve this issue, more data are needed and the existing sampling method should be improved. One possible approach is to combine this algorithm with ensemble learning to avoid the phenomenon of overfitting. 
